UK cost watchdog turns down Amgen’s new cholesterol drug
Amgen’s new injectable cholesterol drug Repatha has been turned down for use on Britain’s state health service, underscoring a worldwide debate about the value of such pricey medicines.
Pharmaceuticals, Biotechnology and Life Sciences
Amgen’s new injectable cholesterol drug Repatha has been turned down for use on Britain’s state health service, underscoring a worldwide debate about the value of such pricey medicines.
US Food and Drug Administration (FDA) has issued a video in which it suggest to pharmacists how to encourage the appropriate use of antibiotics.
Advanced Oncotherapy has disposed of its subsidiary, Oncotherapy Resources Ltd (ORL), for a total cash consideration of £100,000 to Xstrahl.…
The US Food and Drug Administration (FDA) has granted avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Breakthrough…
Anavex is moving forward with the development program for ANAVEX 2-73 for the treatment of Alzheimer’s disease in a…
Steven H. Collis, the President and Chief Executive Officer (CEO) of AmerisourceBergen Corporation will succeed Richard C. Gozon as Chairman of the Board
The European Commission has approved expansion of the indication for Vertex Pharmaceuticals’ Kalydeco, to include children ages 2-5 with cystic fibrosis…
Hikma’s Portuguese facility back into compliance with the US FDA.
The US Food and Drug Administration (FDA) has accepted Sandoz’s Biologics License Application (BLA) for its proposed biosimilar to Amgen’s US-licensed Neulasta (pegfilgrastim) – a recombinant human granulocyte colony-stimulating factor (G-CSF).
Sanofi has appointed Xavier Darcos as President of the Sanofi Espoir Foundation, who succeeds Jean-François Dehecq. Under Dehecq’s Presidency, According to the…